KRAS and lung adenocarcinoma: Targeting of C-Raf rather than of B-Raf kinase could recapitulate the effect of Kras ablation and effectively inhibit tumor development without inducing significant toxicities in mouse models of Kras/Trp53-mutant lung adenocarcinoma.